Katherine Zuniga, NP
Family · Marshall, TXNPI 1982272464
Payments from drug & device makers
Across 250 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$885
- AstraZeneca$469
- Amgen$410
- AbbVie$407
- Lilly USA, LLC$401
- Otsuka America Pharmaceutical, Inc.$229
- plus $2K from 30 others
What the payments were for
- Consulting fees$1754%
- Food & beverage$4,24695%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 54 | $885 |
| AstraZeneca | 27 | $469 |
| Amgen | 17 | $410 |
| AbbVie | 20 | $407 |
| Lilly USA, LLC | 27 | $401 |
| Otsuka America Pharmaceutical, Inc. | 12 | $229 |
| Novo Nordisk | 14 | $208 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $123 |
| Shield Therapeutics Inc | 5 | $112 |
| Halozyme Inc | 1 | $107 |
| Boehringer Ingelheim | 6 | $91 |
| Amarin Pharma, Inc. | 5 | $80 |
| Teva Pharmaceuticals USA, Inc. | 4 | $78 |
| Supernus Pharmaceuticals, Inc. | 5 | $67 |
| Antares Pharma, Inc. | 3 | $66 |
| Kowa Pharmaceuticals America, Inc. | 4 | $65 |
| Exact Sciences | 4 | $63 |
| Axsome Therapeutics, Inc. | 3 | $55 |
| Paratek Pharmaceuticals, Inc. | 3 | $54 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Johnson & Johnson | 3 | $49 |
| Sumitomo Pharma America, Inc. | 3 | $48 |
| Pentax Of America, Inc. | 1 | $38 |
| GSK | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Pfizer | 2 | $30 |
| Lundbeck LLC | 1 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $24 |
| Novartis | 1 | $23 |
| Olympus America Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| CMP Pharma, Inc. | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,458 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $107,507 |
| JardianceEmpagliflozin | 34 | $43,860 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $41,353 |
| MounjaroTirzepatide | 31 | $39,784 |
| FarxigaDapagliflozin Propanediol | 28 | $33,936 |
| EliquisApixaban | 26 | $26,350 |
| LinzessLinaclotide | 11 | $14,002 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $2,290 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,719 |
| Ibandronate Sodium | 24 | $1,593 |
| Gabapentin | 122 | $1,586 |
| ProgesteroneProgesterone, Micronized | 39 | $1,416 |
| Levothyroxine Sodium | 127 | $1,168 |
| Duloxetine Hcl | 68 | $1,065 |
| Atorvastatin Calcium | 135 | $1,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $208 | $107,50793 claims |
| Boehringer IngelheimJardiance | $91 | $43,86034 claims |
| GSKTrelegy Ellipta | $36 | $41,35346 claims |
| Lilly USA, LLCMounjaro | $401 | $39,78431 claims |
| AstraZenecaFarxiga | $469 | $33,93628 claims |
| PfizerEliquis | $30 | $26,35026 claims |
| AbbVieLinzess | $407 | $14,00211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Marshall
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.